MX2021013018A - Formulacion de arnm. - Google Patents
Formulacion de arnm.Info
- Publication number
- MX2021013018A MX2021013018A MX2021013018A MX2021013018A MX2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A MX 2021013018 A MX2021013018 A MX 2021013018A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- mrna molecules
- mrna
- combinations
- molecules encoding
- Prior art date
Links
- 108020004999 messenger RNA Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title abstract 2
- WEYNBWVKOYCCQT-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea Chemical group O1C(CN(C)C)=CC=C1CSCCNC(=O)NC1=CC=C(C)C(Cl)=C1 WEYNBWVKOYCCQT-UHFFFAOYSA-N 0.000 abstract 1
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 102100025221 CD70 antigen Human genes 0.000 abstract 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 abstract 1
- 229930185560 Pseudouridine Natural products 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere al campo de las formulaciones de ARNm y, en particular, proporciona una combinación de una o más moléculas de ARNm que codifican para las proteínas inmunoestimuladoras funcionales CD40L, CD70 y caTLR4; y una o más moléculas de ARNm que codifican para un antígeno. Las combinaciones de la presente invención se caracterizan en particular porque las moléculas de ARNm comprenden una estructura 5'Cap-1 y pueden contener además uno o más nucleósidos modificados, tales como pseudouridinas. La presente invención también proporciona composiciones que comprenden dichas combinaciones y usos de las mismas, en particular en vacunación y tratamiento de trastornos proliferativos celulares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19171323 | 2019-04-26 | ||
| PCT/EP2020/061477 WO2020216911A1 (en) | 2019-04-26 | 2020-04-24 | Mrna formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021013018A true MX2021013018A (es) | 2022-03-11 |
Family
ID=66290283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021013018A MX2021013018A (es) | 2019-04-26 | 2020-04-24 | Formulacion de arnm. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220362360A1 (es) |
| EP (1) | EP3958893A1 (es) |
| JP (1) | JP2022532038A (es) |
| KR (1) | KR20220023340A (es) |
| CN (1) | CN114096272B (es) |
| AU (1) | AU2020263948A1 (es) |
| BR (1) | BR112021021262A2 (es) |
| CA (1) | CA3138011A1 (es) |
| IL (1) | IL287560A (es) |
| MX (1) | MX2021013018A (es) |
| SG (1) | SG11202111720TA (es) |
| WO (1) | WO2020216911A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029164T2 (hu) * | 2007-09-14 | 2017-02-28 | Univ Brussel Vrije | Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra |
| EP3173474A1 (en) * | 2007-09-14 | 2017-05-31 | Vrije Universiteit Brussel | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination |
| US9408909B2 (en) * | 2007-09-14 | 2016-08-09 | Vrije Universiteit Brussel | Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination |
| US20130108663A1 (en) * | 2007-09-14 | 2013-05-02 | Vrije Universiteit Brussel | Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination |
| MX2016006134A (es) | 2013-11-12 | 2017-01-20 | Univ Brussel Vrije | Vector de transcripcion de arn y usos del mismo. |
| MA47515A (fr) * | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
-
2020
- 2020-04-24 CA CA3138011A patent/CA3138011A1/en active Pending
- 2020-04-24 US US17/604,559 patent/US20220362360A1/en active Pending
- 2020-04-24 JP JP2021563262A patent/JP2022532038A/ja active Pending
- 2020-04-24 KR KR1020217038364A patent/KR20220023340A/ko unknown
- 2020-04-24 WO PCT/EP2020/061477 patent/WO2020216911A1/en active Search and Examination
- 2020-04-24 MX MX2021013018A patent/MX2021013018A/es unknown
- 2020-04-24 EP EP20721229.1A patent/EP3958893A1/en active Pending
- 2020-04-24 AU AU2020263948A patent/AU2020263948A1/en active Pending
- 2020-04-24 SG SG11202111720TA patent/SG11202111720TA/en unknown
- 2020-04-24 BR BR112021021262A patent/BR112021021262A2/pt unknown
- 2020-04-24 CN CN202080038101.1A patent/CN114096272B/zh active Active
-
2021
- 2021-10-25 IL IL287560A patent/IL287560A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022532038A (ja) | 2022-07-13 |
| EP3958893A1 (en) | 2022-03-02 |
| CA3138011A1 (en) | 2020-10-29 |
| WO2020216911A1 (en) | 2020-10-29 |
| IL287560A (en) | 2021-12-01 |
| SG11202111720TA (en) | 2021-11-29 |
| US20220362360A1 (en) | 2022-11-17 |
| AU2020263948A1 (en) | 2021-12-23 |
| BR112021021262A2 (pt) | 2021-12-21 |
| CN114096272B (zh) | 2024-08-06 |
| CN114096272A (zh) | 2022-02-25 |
| KR20220023340A (ko) | 2022-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
| ZA202002094B (en) | Trispecific proteins and methods of use | |
| MX2020011257A (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
| PH12020550051A1 (en) | Glp-1 compositions and uses thereof | |
| EA200702656A1 (ru) | Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
| WO2018115097A9 (en) | Ophthalmic composition for treatment of dry eye disease | |
| DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
| CA2366932A1 (en) | Cyclic protein tyrosine kinase inhibitors | |
| EA200802135A1 (ru) | Фармацевтические композиции антагонистического антитела к cd40 | |
| CY1107973T1 (el) | Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων | |
| MXPA06011327A (es) | Azaindoles utiles como inhibidores de jak y otras proteinas cinasas. | |
| SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
| MX2023001877A (es) | Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9. | |
| MX2018000447A (es) | Novedosas proteinas especificas para lag-3. | |
| HRP20100473T1 (hr) | Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c | |
| MX2019014397A (es) | Polipeptidos que enlazan adamts5, mmp13 y agrecano. | |
| MX2024004936A (es) | Variantes de capsides de aav y sus usos. | |
| MX2019008434A (es) | Muteínas de lipocalina con afinidad de unión por lag-3. | |
| MX2019015071A (es) | Composiciones y metodos para tratar tauopatias. | |
| UA87494C2 (en) | Azaindoles useful as inhibitors of jak and other protein kinases | |
| MX2020008125A (es) | Composiciones que comprenden berberina. | |
| EA201991951A1 (ru) | Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения | |
| IL156628A (en) | Use of nk t cells in medical preparation, preparations containing nk t cells and their use in the treatment of immune-related disorders | |
| WO2022256500A3 (en) | Dll3 targeting trispecific proteins and methods of use | |
| MX2024009660A (es) | Variantes de capside de aav y usos de las mismas. |